Richard Peters - Net Worth and Insider Trading
Richard Peters Net Worth
The estimated net worth of Richard Peters is at least $170,153 dollars as of 2024-11-13. Richard Peters is the President and CEO of Yumanity Therapeutics Inc and owns about 90,028 shares of Yumanity Therapeutics Inc (YMTX) stock worth over $170,153. Details can be seen in Richard Peters's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Richard Peters has not made any transactions after 2022-12-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Richard Peters
Richard Peters Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Richard Peters owns 4 companies in total, including Aprea Therapeutics Inc (APRE) , Merrimack Pharmaceuticals Inc (MACK) , and Yumanity Therapeutics Inc (YMTX) among others .
Click here to see the complete history of Richard Peters’s form 4 insider trades.
Insider Ownership Summary of Richard Peters
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
APRE | Aprea Therapeutics Inc | 2020-06-26 | director |
MACK | Merrimack Pharmaceuticals Inc | 2017-02-06 | director & President and CEO |
YMTX | Yumanity Therapeutics Inc | 2022-12-02 | director & President & CEO |
2020-12-22 | director & President & CEO |
Richard Peters Latest Holdings Summary
Richard Peters currently owns a total of 1 stock. Richard Peters owns 90,028 shares of Yumanity Therapeutics Inc (YMTX) as of December 2, 2022, with a value of $170,153.
Latest Holdings of Richard Peters
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
YMTX | Yumanity Therapeutics Inc | 2022-12-02 | 90,028 | 1.89 | 170,153 |
Holding Weightings of Richard Peters
Richard Peters Form 4 Trading Tracker
According to the SEC Form 4 filings, Richard Peters has made a total of 4 transactions in Yumanity Therapeutics Inc (YMTX) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Yumanity Therapeutics Inc is the sale of 10,890 shares on December 2, 2022, which brought Richard Peters around $18,404.
Insider Trading History of Richard Peters
- 1
Richard Peters Trading Performance
Richard Peters Ownership Network
Ownership Network List of Richard Peters
Ownership Network Relation of Richard Peters
Richard Peters Owned Company Details
What does Aprea Therapeutics Inc do?
Who are the key executives at Aprea Therapeutics Inc?
Richard Peters is the director of Aprea Therapeutics Inc. Other key executives at Aprea Therapeutics Inc include President & CEO Oren Gilad , SrVP/CFO/Prin. Fin &Acctg. Off John P. Hamill , and director & President & CEO Christian S Schade .
Aprea Therapeutics Inc (APRE) Insider Trades Summary
Over the past 18 months, Richard Peters made no insider transaction in Aprea Therapeutics Inc (APRE). Other recent insider transactions involving Aprea Therapeutics Inc (APRE) include a net purchase of 3,900 shares made by Oren Gilad , a net purchase of 26,957 shares made by Bernd R. Seizinger , and a net purchase of 23,728 shares made by Marc Duey .
In summary, during the past 3 months, insiders sold 6,462 shares of Aprea Therapeutics Inc (APRE) in total and bought 42,590 shares, with a net purchase of 36,128 shares. During the past 18 months, 6,462 shares of Aprea Therapeutics Inc (APRE) were sold and 69,417 shares were bought by its insiders, resulting in a net purchase of 62,955 shares.
Aprea Therapeutics Inc (APRE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aprea Therapeutics Inc Insider Transactions
Richard Peters Mailing Address
Above is the net worth, insider trading, and ownership report for Richard Peters. You might contact Richard Peters via mailing address: Merrimack Pharmaceuticals, Inc., One Kendall Square, Suite B7201, Cambridge Ma 02139.